» Articles » PMID: 24602563

Emerging Opportunities for the Combination of Molecularly Targeted Drugs with Radiotherapy

Overview
Specialty Oncology
Date 2014 Mar 8
PMID 24602563
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Recent drug discovery developments in the field of small molecule targeted agents have led to much interest in combining these with radiotherapy. There are good preclinical data to suggest this approach worthy of investigation and in this review we discuss how this has translated into recent clinical trials. The outcome of clinical trials investigating radiotherapy/targeted drug combinations published in the last 5 years is discussed, as are trials in progress. The perceived future opportunities and challenges in the development of this exciting area are considered.

Citing Articles

Combination of Radiotherapy and Targeted Agents in Brain Metastasis: An Update.

Aly Z, Peereboom D Curr Treat Options Neurol. 2016; 18(7):32.

PMID: 27225542 DOI: 10.1007/s11940-016-0416-3.


Targeted therapy combined with radiotherapy in non-small-cell lung cancer: a review of the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).

Counago F, Rodriguez A, Calvo P, Luna J, Monroy J, Taboada B Clin Transl Oncol. 2016; 19(1):31-43.

PMID: 27106020 DOI: 10.1007/s12094-016-1512-2.


Exploiting biological and physical determinants of radiotherapy toxicity to individualize treatment.

Scaife J, Barnett G, Noble D, Jena R, Thomas S, West C Br J Radiol. 2015; 88(1051):20150172.

PMID: 26084351 PMC: 4628540. DOI: 10.1259/bjr.20150172.


Role of radiotherapy in metastatic non-small cell lung cancer.

Faria S Front Oncol. 2014; 4:229.

PMID: 25353005 PMC: 4195278. DOI: 10.3389/fonc.2014.00229.